Greenwich LifeSciences, Inc. financial data

Symbol
GLSI on Nasdaq
Location
Stafford, TX
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 84% % 565%
Return On Equity -1043% % -463%
Return On Assets -565% % -244%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13,854,539 shares 5.4%
Common Stock, Shares, Outstanding 13,794,577 shares 4.9%
Entity Public Float $101,000,000 USD 79%
Common Stock, Value, Issued $13,795 USD 4.9%
Weighted Average Number of Shares Outstanding, Basic 13,641,384 shares 3.8%
Weighted Average Number of Shares Outstanding, Diluted 13,641,384 shares 3.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $15,788,207 USD 73%
General and Administrative Expense $3,798,881 USD 132%
Operating Income (Loss) $19,587,088 USD -82%
Net Income (Loss) Attributable to Parent $19,475,704 USD -86%
Earnings Per Share, Basic -1 USD/shares -86%
Earnings Per Share, Diluted -1 USD/shares -86%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $3,806,978 USD -35%
Assets $3,806,978 USD -35%
Accounts Payable, Current $1,047,881 USD
Employee-related Liabilities, Current $206,834 USD 206%
Liabilities, Current $1,622,001 USD 93%
Liabilities $1,622,001 USD 93%
Retained Earnings (Accumulated Deficit) $77,588,863 USD -34%
Stockholders' Equity Attributable to Parent $2,184,977 USD -56%
Liabilities and Equity $3,806,978 USD -35%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,834,454 USD -2.9%
Net Cash Provided by (Used in) Financing Activities $492,423 USD 65%
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 13,794,577 shares 4.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,342,031 USD 9.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3,806,978 USD -35%
Deferred Tax Assets, Valuation Allowance $6,297,696 USD 40%
Deferred Tax Assets, Operating Loss Carryforwards $6,297,696 USD 40%
Share-based Payment Arrangement, Expense $4,221,106 USD 129%